Document is current
Any future updates will be listed below
-
Authors
Pöytäkangas, Teemu
Basnyat, Pabitra
Saarinen, Jukka
Rainesalo, Sirpa
Peltola, Jukka
-
Funding
Funding for this research was provided by:
Tampere University
- License Information
-
More Information
Article History
Received: 27 January 2026
Accepted: 23 March 2026
First Online: 2 April 2026
Declarations
:
: As the study involved no contact with patients, ethical committee approval and informed consent were not required under the Finnish Law on Research. In accordance with Finnish guidelines, the study was approved by the Head of the Tampere University Science Centre and followed the tenets of the Declaration of Helsinki.
: None.
: T.P, P.B, J.S, and S.R report no conflicts of interest. J.P has participated in clinical trials for Bial, Biohaven, Eisai, and UCB; received research grants from Angelini Pharma, Jazz Pharma, Eisai, Medtronic, UCB, and LivaNova; received speaker honoraria from Angelini Pharma, Eisai, Jazz Pharma, LivaNova, Medtronic, Orion Pharma, Takeda and UCB; received support for travel to congresses from LivaNova, Eisai, Medtronic, and UCB; and participated in advisory boards for Angelini Pharma, Eisai, Jazz Pharma, LivaNova, Medtronic, Novartis, Pfizer, and UCB.
